Literature DB >> 20598680

Pregabalin inhibits accelerated defecation and decreased colonic nociceptive threshold in sensitized rats.

Katsuyo Ohashi-Doi1, Jeremy D Gale, Yoichi Kurebayashi.   

Abstract

Pregabalin, a ligand of alpha(2)delta subunits of voltage-gated calcium channels, reduces visceral hypersensitivity associated with irritable bowel syndrome. However, effects of pregabalin on bowel function are not well described. We investigated the effects of pregabalin on bowel dysfunction and colonic nociceptive threshold in sensitized rats. Increased fecal pellet output was evoked by non-ulcerogenic stress. Decreased colonic nociceptive threshold was induced in separate rats by administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS) into the lumen of the proximal colon. Fecal pellet output was significantly increased during 2h restraint stress. Oral pregabalin (10-100mg/kg, p.o.) inhibited this increased fecal output dose-dependently, but did not change fecal output in naïve rats. The response threshold to distension of the non-inflamed distal colon was significantly decreased seven days after TNBS administration. An anti-hyperalgesic effect of pregabalin (30-100mg/kg, p.o.) that opposed the decreased colonic nociceptive threshold in TNBS-sensitized rats was observed, but nociceptive thresholds were not changed in naïve rats. Moreover, pregabalin was more potent in reducing disturbed defecation compared with reduction in nociceptive threshold to distension in TNBS-sensitized rats. This is the first report that pregabalin modulates stress-induced defecation in rats. These data indicate that pregabalin can ameliorate both altered defecation and decreases in colonic nociceptive threshold, suggesting that pregabalin might warrant investigation for the treatment of irritable bowel syndrome. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598680     DOI: 10.1016/j.ejphar.2010.06.014

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  The use of non-narcotic pain medication in pediatric gastroenterology.

Authors:  Adrian Miranda; Miguel Saps
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

2.  Alpha 2 Delta (α(2)δ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome.

Authors:  Jeremy D Gale; Lesley A Houghton
Journal:  Front Pharmacol       Date:  2011-06-09       Impact factor: 5.810

3.  Evaluation of Antinociceptive Effect of Pregabalin in Mice and its Combination with Tramadol using Tail Flick Test.

Authors:  Fariborz Keyhanfar; Manzumeh Shamsi Meymandi; Gholamreza Sepehri; Ramin Rastegaryanzadeh; Gioia Heravi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

4.  The Contribution of NMDA Receptors in Antinociceptive Effect of Pregabalin: Comparison of Two Models of Pain Assessment.

Authors:  Manzumeh Shamsi Meymandi; Fariborz Keyhanfar; Gholam Reza Sepehri; Gioia Heravi; Omid Yazdanpanah
Journal:  Anesth Pain Med       Date:  2017-06-21

Review 5.  Visceral pain: the ins and outs, the ups and downs.

Authors:  Shafaq Sikandar; Anthony H Dickenson
Journal:  Curr Opin Support Palliat Care       Date:  2012-03       Impact factor: 2.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.